Drugs / DENVax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01110551 | May 2010 → Apr 2012 | dengue disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DENVax | “DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera...” NCT01110551 ↗ |
| Modality | Vaccine | “live attenuated dengue vaccine” NCT01110551 ↗ |
| Route | Subcutaneous | “DENVax administered subcutaneously.” NCT01110551 ↗ |